Demonstrating a general responsiveness of melanoma cells to ERK inhibition, both BRAF-mutated and BRAF-WT cells responded with strong loss of cell viability to combination treatments with SCH772984/S63845 (A-375, 8%; Mel-HO, 11%; MeWo, 17%; SK-Mel-23, 7%; 10 μM SCH772984/1 μM S63845; 48 h; Figure 1). Here, BRAF is linked to melanoma.